Lexeo Therapeutics Announces Strategic Investment From Sarepta Therapeutics To Support Development Of Lexeo’s Cardiovascular Gene Therapies
Round Type
Corporate Round
New York CityBiotechnologyHealth CareGeneticsTherapeuticsDescription
LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined sub-group of Alzheimer’s disease, today announced a strategic investment from Sarepta Therapeutics, Inc. (Sarepta) to support the advancement of LEXEO’s adeno-associated virus (AAV) gene therapy programs. In connection with this investment, the companies will explore the development of novel gene therapy candidates for a range of cardiovascular diseases.
Quick answer
Lexeo Therapeutics raised an undisclosed amount in a Corporate Round round, dated August 28, 2023. Lexeo Therapeutics is based in New York City, New York, United States.
- How much did Lexeo Therapeutics raise?
- Lexeo Therapeutics raised an undisclosed amount in a Corporate Round round on August 28, 2023.
- What does Lexeo Therapeutics do?
- Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated.
- Where is Lexeo Therapeutics based and how big is it?
- Lexeo Therapeutics is based in New York City, New York, United States.
- Who are the decision-makers at Lexeo Therapeutics?
- Fundz holds 1 contact at Lexeo Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Genetics and Therapeutics around the same time
Companies in the same sectors as Lexeo Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Amicus Therapeutics raised an undisclosed amount (Funding Round) on October 2, 2023.
- Acasti raised $7.5M (Post-IPO Equity) on September 26, 2023.
- Acasti raised $7.5M on September 25, 2023.
- Qihan Biotech raised an undisclosed amount (Series B) on September 23, 2023.
- DalCor Pharmaceuticals raised $80M (Series D) on September 13, 2023.
- Renibus Therapeutics raised an undisclosed amount (Series B) on September 12, 2023.
Who to call at Lexeo Therapeutics, and when
A new round usually means Lexeo Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Lexeo Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Lexeo Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Lexeo Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Lexeo Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Lexeo Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.